Mentor Capital's Cancer Fighting Investment Shows Great Range of Application in University Agreement

(For Immediate Release December 2, 2009)  

SAN DIEGO,  Mentor Capital, Inc. (Pink Sheets: MNTR) from the onset selected to invest in one cancer company, Quantum Immunologics, whose immunotherapy, in Mentor's independent medical analysis, may well be expected to apply to many cancer lines. This was financially preferable to investing separately in many cancer companies whose products each attack one cancer type.  By investing early, before the multiple product lines were developed by Quantum, Mentor was able to invest at the price for one line, but now may look forward to receiving the value from the development of many.  All, of course, only after treatments are vetted through FDA-authorized testing. 

In 2009, Quantum received FDA authorization to apply its exclusively licensed, patented immunotherapy in a Phase I/II human clinical study which involves 27 patients with advanced-stage metastatic breast cancer and is designed around the company's proprietary dendritic cell therapy. Other, already noticed but not definitively announced joint actions, will involve the FDA-authorized testing, and if that's successful, the commercial development of immunotherapy treatments for other cancer types in men and women.  However, the surprising breadth of potential application of the financed cancer fighting immunotherapy is best illustrated by the current press release by Mentor's major investee. 

Quantum Immunologics, announced it will extend its novel cancer immunotherapy to the veterinary market through the formation, with Auburn University, of a new, jointly-owned and independently-funded company.  The partnership is targeted to begin operation in mid-2010 and will draw both on the University's renowned College of Veterinary Medicine animal oncology expertise and will license Quantum's proprietary oncofetal antigen-based therapy as its underlying technology. 

Mentor Capital's public market value should closely track the major investment it holds in this rapidly growing biotech investee, an otherwise private company. At today's $1.50 per Mentor share the implied valuation of 100% of Quantum is $7 Million. To continue to add value for existing and new shareholders, Mentor is working to significantly increase its investment in Quantum.   

Additional information on Mentor Capital and links to Quantum Immunologics may be referenced from the company website: www.MentorCapital.com.    

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.   

For further information contact:  

Chet Billingsley, CEO 

Mentor Capital, Inc. 

P.O. Box 1709 

Ramona, CA  92065